Raymond James lowered the firm’s price target on Lumexa Imaging (LMRI) to $17 from $23 and keeps a Strong Buy rating on the shares following Q4 earnings. The firm notes the company’s better than expected results were overshadowed by a soft Q1 outlook, divergence from the IPO expectations on cash flow and adjusted EBITDA addbacks and some communication issues.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LMRI: